X0206 3 2013-05-21 0 0001269021 PORTOLA PHARMACEUTICALS INC PTLA 0001252522 GALAKATOS NICHOLAS C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON MA 02116 1 0 0 0 Series A Convertible Preferred Stock Common Stock 15642 I MPM Asset Management Investors 2003 BVIII LLC Series A Convertible Preferred Stock Common Stock 68280 I MPM Bioventures III GmbH & Co. Beteiligungs KG Series A Convertible Preferred Stock Common Stock 24400 I MPM BioVentures III Parallel Fund, L.P. Series A Convertible Preferred Stock Common Stock 54323 I MPM BioVentures III, L.P. Series A Convertible Preferred Stock Common Stock 807939 I MPM BioVentures III-QP, L.P. Series B Convertible Preferred Stock Common Stock 10710 I MPM Asset Management Investors 2003 BVIII LLC Series B Convertible Preferred Stock Common Stock 46752 I MPM Bioventures III GmbH & Co. Beteiligungs KG Series B Convertible Preferred Stock Common Stock 16707 I MPM BioVentures III Parallel Fund, L.P. Series B Convertible Preferred Stock Common Stock 37196 I MPM BioVentures III, L.P. Series B Convertible Preferred Stock Common Stock 553204 I MPM BioVentures III-QP, L.P. Series C Convertible Preferred Stock Common Stock 10658 I MPM Asset Management Investors 2003 BVIII LLC Series C Convertible Preferred Stock Common Stock 46526 I MPM Bioventures III GmbH & Co. Beteiligungs KG Series C Convertible Preferred Stock Common Stock 16625 I MPM BioVentures III Parallel Fund, L.P. Series C Convertible Preferred Stock Common Stock 37016 I MPM BioVentures III, L.P. Series C Convertible Preferred Stock Common Stock 550530 I MPM BioVentures III-QP, L.P. Series D Convertible Preferred Stock Common Stock 2334 I MPM Asset Management Investors 2003 BVIII LLC Series D Convertible Preferred Stock Common Stock 10189 I MPM Bioventures III GmbH & Co. Beteiligungs KG Series D Convertible Preferred Stock Common Stock 3641 I MPM BioVentures III Parallel Fund, L.P. Series D Convertible Preferred Stock Common Stock 8106 I MPM BioVentures III, L.P. Series D Convertible Preferred Stock Common Stock 120566 I MPM BioVentures III-QP, L.P. The Series A Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 1 share of Series A Preferred Stock, for no additional consideration. MPM BioVentures III GP, L.P. and MPM BioVentures III LLC ("MPM III LLC") are the direct and indirect general partners of MPM BioVentures III, L.P., MPM BioVentures III-QP, L.P., MPM BioVentures III GmbH & Co. Beteiligungs KG and MPM BioVentures III Parallel Fund, L.P. Dr. Galakatos is a Series A member of MPM BioVentures III LLC and Manager of MPM Asset Management Investors 2003 BVIII LLC and shares voting and dispositive power over the shares held by MPM BioVentures III, L.P., MPM BioVentures III-QP, L.P., MPM BioVentures III GmbH & Co. Beteiligungs KG, MPM BioVentures III Parallel Fund, L.P. and MPM Asset Management Investors 2003 BVIII LLC. Dr. Galakatos disclaims beneficial ownership of the shares identified in this footnote except to the extent of his respective proportionate pecuniary interest in such shares. The Series B Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 1 share of Series B Preferred Stock, for no additional consideration. The Series C Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 1 share of Series C Preferred Stock, for no additional consideration. The Series D Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 1 share of Series D Preferred Stock, for no additional consideration. /s/ Sally A. Kay, as attorney-in-fact 2013-05-21